The global imatinib drug market is estimated to grow at a CAGR of around 4% during the forecast period. The major factors contributing to the growth of the market include the rising prevalence of cancer and an increase in awareness programs towards cancer by government and private organizations. Imatinib is a chemotherapy drug that used to slow down or stopping the growth of the cancer cells. This medication is used for the treatment of certain types of cancer including, acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic syndrome. Imatinib drug helps in improving blood count which makes it highly effective and attracting the target patients for the adoption of this drug leading to the significant growth of the imatinib drug market.

Free Sample Copy @ https://www.omrglobal.com/request-sample/imatinib-drug-market

Geographically, the global imatinib drug market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold a major share in the market owing to the growing concern towards healthcare. According to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer are diagnosed in the US whereas around 600,000 died of cancer. The high prevalence of cancer is augmenting the growth of the imatinib drug market as leukemia is one of the most common cancers in the US. The presence of major companies in the region is propelling the growth of imatinib drug. These companies are significantly focusing on marketing their products across the globe and gain a competitive advantage.

A Full Report of Global Imatinib Drug Market is Available at:
https://www.omrglobal.com/industry-reports/imatinib-drug-market

The global imatinib drug market is segmented based on drug form, and application. Based on drug form, the market is classified into tablets and capsules. Based on application the market is classified into blood cancer (leukemia and other blood cancers), gastrointestinal stromal tumors (GIST), skin tumors (dermatofibrosarcoma protuberans), and other tumors such as systemic mastocytosis. Blood cancer segment is expected to hold the major market share owing to increasing demand for imatinib for the treatment of different types of leukemia cancers such as Acute myeloid (or myelogenous) leukemia (AML), Chronic myeloid (or myelogenous) leukemia (CML), Acute lymphocytic (or lymphoblastic) leukemia (ALL), and Chronic lymphocytic leukemia (CLL).

Global Imatinib Drug Market – Segmentation
By Application 
Food and Beverages
Chemical
Pharmaceutical
Others
Global Imatinib Drug Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles

Apotex Inc.
Cipla, Inc.
Dr. Reddy’s Laboratory, Ltd.
Glenmark Pharmaceutical, Ltd.
Lupin, Ltd.
Mylan N.V.
Novartis AG
Sun Pharmaceutical Industries, Ltd.
Teva Pharmaceutical Industry, Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/imatinib-drug-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404